Annette von Delft

7PUBLICATIONS
35CO-AUTHORS
Cheminformatics and quantitative structure-activity relationshipsMolecular targetsBiologically active moleculesProteins and peptidesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 16, 2025
Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor.

Ed J Griffen, Daren Fearon, Briana L McGovern

|Jan 11, 2024
An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.

Benediktus Yohan Arman, Juliane Brun, Michelle L Hill

|Nov 09, 2023
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.

Melissa L Boby, Daren Fearon, Matteo Ferla

|May 12, 2023
Accelerating antiviral drug discovery: lessons from COVID-19.

Annette von Delft, Matthew D Hall, Ann D Kwong

|Dec 20, 2021
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia.

Arne W Mould, Noura Al-Juffali, Annette von Delft

|Jun 20, 2020
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.

Ilaria Esposito, Paola Cicconi, Anna Morena D'Alise

Pageof 2

Frequent Collaborators

2 joint publications

Mariano Stornaiuolo

2 joint publications

John D Chodera

1 joint publications

Ilaria Esposito

1 joint publications

Paola Cicconi